BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Clemmesen JO, Giraldi A, Ott P, Dalhoff K, Hansen BA, Larsen FS. Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis. World J Gastroenterol 2008; 14(40): 6208-6212 [PMID: 18985812 DOI: 10.3748/wjg.14.6208]
URL: https://www.wjgnet.com/1007-9327/full/v14/i40/6208.htm
Number Citing Articles
1
Jitender Thakur, Sahaj Rathi, Sandeep Grover, Madhu Chopra, Swastik Agrawal, Sunil Taneja, Ajay Duseja, Anil Bhansali, Yogesh K. Chawla, Radha K. Dhiman. Tadalafil, a Phosphodiesterase-5 Inhibitor, Improves Erectile Dysfunction in Patients With Liver CirrhosisJournal of Clinical and Experimental Hepatology 2019; 9(3): 312 doi: 10.1016/j.jceh.2018.07.007
2
Philipp Schwabl, Wim Laleman. Novel treatment options for portal hypertensionGastroenterology Report 2017; 5(2): 90 doi: 10.1093/gastro/gox011
3
Rakesh Kumar Jagdish. Sexual dysfunctions and their treatment in liver diseasesWorld Journal of Hepatology 2022; 14(8): 1530-1540 doi: 10.4254/wjh.v14.i8.1530
4
Amel M.M. Abdel-Hafez, Manal A. Othman. Effect of sildenafil citrate on the structure of rat liverThe Egyptian Journal of Histology 2013; 36(4): 991 doi: 10.1097/01.EHX.0000440847.85696.1c
5
Puneeta Tandon, Irteza Inayat, Michael Tal, Marcelo Spector, Martha Shea, Roberto J. Groszmann, Guadalupe Garcia–Tsao. Sildenafil Has No Effect on Portal Pressure but Lowers Arterial Pressure in Patients With Compensated CirrhosisClinical Gastroenterology and Hepatology 2010; 8(6): 546 doi: 10.1016/j.cgh.2010.01.017
6
Rafael Paternostro, Birgit B. Heinisch, Thomas Reiberger, Mattias Mandorfer, Remy Schwarzer, Berit Seeland, Michael Trauner, Markus Peck‐Radosavljevic, Arnulf Ferlitsch. Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertensionLiver International 2018; 38(8): 1427 doi: 10.1111/liv.13704
7
Susana G. Rodrigues, Yuly P. Mendoza, Jaime Bosch. Investigational drugs in early clinical development for portal hypertensionExpert Opinion on Investigational Drugs 2022; 31(8): 825 doi: 10.1080/13543784.2022.2095259
8
Sergi Guixé-Muntet, Sergio Quesada-Vázquez, Jordi Gracia-Sancho. Pathophysiology and therapeutic options for cirrhotic portal hypertensionThe Lancet Gastroenterology & Hepatology 2024; 9(7): 646 doi: 10.1016/S2468-1253(23)00438-7
9
Wolfgang Kreisel, Peter Deibert, Limas Kupcinskas, Jolanta Sumskiene, Beate Appenrodt, Susanne Roth, Michaela Neagu, Martin Rössle, Alexander Zipprich, Karel Caca, Arnulf Ferlitsch, Karin Dilger, Ralf Mohrbacher, Roland Greinwald, Tilman Sauerbruch. The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-studyDigestive and Liver Disease 2015; 47(2): 144 doi: 10.1016/j.dld.2014.10.018
10
Wolfgang Kreisel, Denise Schaffner, Adhara Lazaro, Jonel Trebicka, Irmgard Merfort, Annette Schmitt-Graeff, Peter Deibert. Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal HypertensionInternational Journal of Molecular Sciences 2020; 21(17): 6223 doi: 10.3390/ijms21176223
11
A. Friedl, R. Schwarzer, J. Schneeweiss, C. Brössner. Urologische Aspekte bei Patienten mit LeberzirrhoseDer Urologe 2016; 55(1): 63 doi: 10.1007/s00120-015-3978-x
12
Shao-Jung Hsu, Hui-Chun Huang, Chiao-Lin Chuang, Ching-Chih Chang, Ming-Chih Hou, Fa-Yauh Lee, Shou-Dong Lee. Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive RatsPharmaceutics 2020; 12(4): 320 doi: 10.3390/pharmaceutics12040320
13
Rakesh Kumar Jagdish, Ahmed Kamaal, Saggere Muralikrishna Shasthry, Jaya Benjamin, Rakhi Maiwall, Ankur Jindal, Ashok Choudhary, Vijayaraghavan Rajan, Vinod Arora, Ankit Bhardwaj, Guresh Kumar, Manoj Kumar, Shiv K. Sarin. Tadalafil improves erectile dysfunction and quality of life in men with cirrhosis: a randomized double blind placebo controlled trialHepatology International 2023; 17(2): 434 doi: 10.1007/s12072-021-10264-w
14
John J. Reho, Xiaoxu Zheng, Steven A. Fisher. Smooth muscle contractile diversity in the control of regional circulationsAmerican Journal of Physiology-Heart and Circulatory Physiology 2014; 306(2): H163 doi: 10.1152/ajpheart.00493.2013
15
Leonie Halverscheid, Peter Deibert, René Schmidt, Hubert E Blum, Torsten Dunkern, Benedikt HJ Pannen, Wolfgang Kreisel. Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liverBMC Gastroenterology 2009; 9(1) doi: 10.1186/1471-230X-9-69
16
Shuet Fong Neong, Emma O. Billington, Stephen E. Congly. Sexual Dysfunction and Sex Hormone Abnormalities in Patients With Cirrhosis: Review of Pathogenesis and ManagementHepatology 2019; 69(6): 2683 doi: 10.1002/hep.30359
17
Frank E. Uschner, Kathleen Glückert, Rafael Paternostro, Thorsten Gnad, Robert Schierwagen, Mattias Mandorfer, Fernando Magdaleno, Cristina Ortiz, Katharina Schwarzkopf, Patrick S. Kamath, Carlo Alessandria, Christoph Boesecke, Alexander Pfeifer, Thomas Reiberger, Wolfgang Kreisel, Tilman Sauerbruch, Arnulf Ferlitsch, Jonel Trebicka, Sabine Klein. Combination of phosphodiesterase‐5‐inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunctionLiver International 2020; 40(9): 2228 doi: 10.1111/liv.14586
18
Alok Kumar, Vivek Saraswat, Gaurav Pande, Rajesh Kumar. Does Treatment of Erectile Dysfunction With PDE 5 Inhibitor Tadalafil Improve Quality of Life in Male Patients With Compensated Chronic Liver Disease? A Prospective Pilot StudyJournal of Clinical and Experimental Hepatology 2022; 12(4): 1083 doi: 10.1016/j.jceh.2022.01.009
19
Hye Jin Yoo, Bora Lee, Eun-Ae Jung, Sang Gyune Kim, Young Seok Kim, Jeong-Ju Yoo. Prevalence and risk factors of erectile dysfunction in patients with liver cirrhosis: a systematic review and meta-analysisHepatology International 2023; 17(2): 452 doi: 10.1007/s12072-021-10270-y
20
Javier Blanco-Rivero, Fabiano E. Xavier. Therapeutic Potential of Phosphodiesterase Inhibitors for Endothelial Dysfunction- Related DiseasesCurrent Pharmaceutical Design 2020; 26(30): 3633 doi: 10.2174/1381612826666200403172736
21
Wolfgang Kreisel, Adhara Lazaro, Jonel Trebicka, Markus Grosse Perdekamp, Annette Schmitt-Graeff, Peter Deibert. Cyclic GMP in Liver Cirrhosis—Role in Pathophysiology of Portal Hypertension and Therapeutic ImplicationsInternational Journal of Molecular Sciences 2021; 22(19): 10372 doi: 10.3390/ijms221910372
22
Guanghui Zang, Xv Sun, Yufeng Sun, Yan Zhao, Yang Dong, Kun Pang, Ping Cheng, Meng Wang, Yuli Zheng. Chronic liver diseases and erectile dysfunctionFrontiers in Public Health 2023; 10 doi: 10.3389/fpubh.2022.1092353
23
Batool AbuHalimeh, Michael J. Krowka, Adriano R. Tonelli. Treatment Barriers in Portopulmonary HypertensionHepatology 2019; 69(1): 431 doi: 10.1002/hep.30197
24
Denise Schaffner, Adhara Lazaro, Peter Deibert, Peter Hasselblatt, Patrick Stoll, Lisa Fauth, Manfred W Baumstark, Irmgard Merfort, Annette Schmitt-Graeff, Wolfgang Kreisel. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertensionWorld Journal of Gastroenterology 2018; 24(38): 4356-4368 doi: 10.3748/wjg.v24.i38.4356
25
Peter Hauff, Ulrich Gottwald, Matthias Ocker. Early to Phase II drugs currently under investigation for the treatment of liver fibrosisExpert Opinion on Investigational Drugs 2015; 24(3): 309 doi: 10.1517/13543784.2015.997874
26
Seohyuk Lee, Saad Saffo. Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapyWorld Journal of Gastroenterology 2023; 29(1): 61-74 doi: 10.3748/wjg.v29.i1.61
27
Harikumar Nair, Annalisa Berzigotti, Jaime Bosch. Emerging therapies for portal hypertension in cirrhosisExpert Opinion on Emerging Drugs 2016; 21(2): 167 doi: 10.1080/14728214.2016.1184647
28
Moein Ala, Razieh Mohammad Jafari, Ahmad Reza Dehpour. Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indicationsFundamental & Clinical Pharmacology 2021; 35(2): 235 doi: 10.1111/fcp.12633
29
Hui Li. Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis, cirrhosis and hepatocellular carcinomaDigestive and Liver Disease 2022; 54(5): 598 doi: 10.1016/j.dld.2021.07.006